References
- Meunier PJ, Delmas PD, Eastell R, et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. Clin Ther 1999;21:1025–44
- Osteoporose. Tweede Herziene Richtlijn: Kwaliteitsinstituut voor de Gezondheidszorg CBO, 2002
- Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. New Engl J Med 2004;350:1189–99
- McClung MR. Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother 2000;1:225–38
- Ettinger B, Li DK, Klein R. Alendronate use among 812 women: prevalence of gastrointestinal compliants, noncompliance with patient instructions, and discontinuation. J Managed Care Pharmacy 1998;32: 488–92
- McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271–87
- Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856–61
- Penning-van Beest FJA, Goettsch WG, Erkens JA, Herings RMC. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006;28:236–42
- Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
- Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2005
- Baker DE. Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Rev Gastroenterol Disord 2002;2:20–33
- Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004;26:245–56
- Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895–903
- Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002;24:1871–86
- Kendler D, Kung AW, Fuleihan Gel H, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004;48:243–51
- Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 2004;15:1003–8
- Herings RM. PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in The Netherlands. Utrecht: Utrecht University; 1993
- Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value in Health 2000;3:417–26
- Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993–1000
- Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003;158:77–84
- Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporosis Int 2004;15:120–4
- Staa TPv, Leufkens HGM, Cooper C. Utility of medical and drug history in fracture risk prediction among men and women. Bone 2002;31:508–14
- Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. J Am Med Assoc 2004;292: 1326–32
- Herings RM, Klungel OH. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Pharmacoeconomics 2001;19:655–65
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report No. 843 Geneva: World Health Organization; 1994
- Dennison E, Cooper C. Epidemiology of osteoporotic fractures. Horm Res 2000;54(Suppl 1):58–63